STAT

DECEMBER 26, 2023

There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too. Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nur

Hospitals 363

Hospitals Nursing Homes 363

Express Pharma

DECEMBER 26, 2023

Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. This application paves the way for Phase I trial of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have not responded to Bacillus Calmette-Guérin (BCG) therapy, making it globally the second saRNA drug to advance into the clinical stage, says GlobalData.

Vaccines 96

Vaccines 96

STAT

DECEMBER 26, 2023

Food-as-medicine programs that address food insecurity and diet-related chronic diseases have drawn widespread attention from policymakers , payers, and health care providers. But what is the evidence that such programs work as intended? Some research suggests that food as medicine can improve health and lower health care costs, but until now there has been little evidence from randomized clinical trials.

Diabetes 309

Diabetes 309

Express Pharma

DECEMBER 26, 2023

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharma company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. The proposed acquisition will add to AstraZeneca’s pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, a potential new treatment for multiple myeloma, as well as

Immunity 92

Immunity Immunization 92

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 26, 2023

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier. The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sle

306

306

Express Pharma

DECEMBER 26, 2023

Informa Markets in India recently organised the CPHI & PMEC India 2023 at the India Expo Centre in Greater Noida, Delhi-NCR. A statement from Informa markets informed, “As the largest and most exhaustive pharma industry gathering in South Asia, CPHI and PMEC India expo, drew an overwhelming positive response, attracting over 48,000 attendees from 120+ countries in a vast 100,000 sq m exhibition space.

Pharmaceutical Manufacturing 90

Pharmaceutical Manufacturing 90

Express Pharma

DECEMBER 26, 2023

Industry leader Sameer Joshi, COO & CCO, Cepham Inc., US, moderates an intriguing conversation between Len Monheit, CEO, Trust Transparency Center, and Jon Benninger, Vice President, Informa Markets US. The discussion centers on ‘Exploring the Critical Need for Transparency in the Nutraceutical Supply Chain: A Deep Dive into the Importance of Source Verification, Manufacturing Processes, and Regulatory Compliance to Ensure Product Quality and Consumer Safety.

86

86

STAT

DECEMBER 26, 2023

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules. Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024: Lobbying power of AI, software-enabled devices Medtech lobby AdvaMed announced earlier this month that the major med

277

277

Pharmaceutical Technology

DECEMBER 26, 2023

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.

97

97

STAT

DECEMBER 26, 2023

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer. RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals , which pair the tumor-killing power of radiation with the precision of targeted cancer therapies.

265

265

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

DECEMBER 26, 2023

Exploring the powerful collaborations between scientists, investors, and the medical community in finding breakthrough treatments for major diseases, and the notion of 'healthspan'

73

73

Big Molecule Watch

DECEMBER 26, 2023

As an update to our previous report , Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced the successful completion of the transition of the acquired biosimilars business in approximately 120 countries, a year ahead of schedule. On December 18, 2023, IAVI, a global nonprofit scientific research organization, and Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, announced that the Bill & Melinda Gates Foundation has awarded IAVI $55 million to conduct a Phase IIb t

Biosimilars 62

Biosimilars Vaccines Hospitals 62

pharmaphorum

DECEMBER 26, 2023

In the first of a five-part festive instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Advarra’s chief product officer, Elisa Cascade, about the reasons behind increasing burdens on clinical research sites over the last five years.

67

67

Big Molecule Watch

DECEMBER 26, 2023

On December 15, 2023, Vertex announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

62

62

Drug Patent Watch

DECEMBER 26, 2023

Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Express Pharma

DECEMBER 26, 2023

Aurobindo Pharma’s wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Noxafil Injection, 300 mg/16.7 mL (18 mg/mL), of Merck Sharp & Dohme LLC (Merck).

Chemotherapy 59

Chemotherapy 59

Drug Patent Watch

DECEMBER 26, 2023

Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents… The post New patent for Blueprint Medicines drug AYVAKIT appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmaceutical Business Review

DECEMBER 26, 2023

A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two or more systemic treatments earlier. The regulatory agency accepted the BLA, with a decision on the drug approval anticipated on 26 June 2024. The latest development comes after the FDA awarded breakthrough therapy designation for patritumab deruxtecan in December 2021.

Labelling 59

Labelling 59

Drug Patent Watch

DECEMBER 26, 2023

Annual Drug Patent Expirations for COREG+CR Coreg Cr is a drug marketed by Woodward and is included in one NDA. It is available from four suppliers. There are two patents… The post New patent expiration for Woodward drug COREG CR appeared first on DrugPatentWatch - Make Better Decisions.

59

59

PharmaState Academy

DECEMBER 26, 2023

Registrations, Starting Soon! WORKSHOP International Pharma Marketing Career Development Workshop Session 1: Foundation & Industry Understanding January 21, 2024 11:30 AM - 12:30 PM Days Hours Minutes Seconds What will you learn? As you will join us for ‘Session 01: Foundation and Industry Understanding’, we shall explore the educational pathways and qualifications necessary to succeed in the pharmaceutical industry.

52

52

RX Note

DECEMBER 26, 2023

Introduction Burns are characterized as First degree - Red/painful, minor swelling. Second degree - Thicker, very painful, produce blisters. Third degree - Damage to all layers of skin, appears white or charred. The Need of Referral Burns from chemical or electricity exposure or in immunosuppressed patients should be referred for emergency medical care.

Mayo Clinic 52

Mayo Clinic Diabetes Community Pharmacies 52

The Guardian - Pharmaceutical Industry

DECEMBER 26, 2023

Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market. The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.

52

52

pharmaphorum

DECEMBER 26, 2023

AstraZeneca agrees a $1.

94

94

PharmExec

DECEMBER 26, 2023

As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.

64

64

Pharmaceutical Technology

DECEMBER 26, 2023

ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

52

52

Pharmaceutical Commerce

DECEMBER 26, 2023

Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.

52

52

Pharmaceutical Technology

DECEMBER 26, 2023

Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.

52

52

PharmExec

DECEMBER 26, 2023

Five trends in pharmaceutical marketing from the past year.

59

59

Pharmaceutical Technology

DECEMBER 26, 2023

MRTX-1719 is under clinical development by Mirati Therapeutics and currently in Phase II for Biliary Tumor.

52

52

PharmaTech

DECEMBER 26, 2023

WHO provides a look at the world’s health as the agency turns 75.

52

52

Pharmaceutical Technology

DECEMBER 26, 2023

In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.

52

52

Pharmacy Times

DECEMBER 26, 2023

From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.

26

26

Pharmaceutical Technology

DECEMBER 26, 2023

NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.

52

52

Pharmacy Times

DECEMBER 26, 2023

From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.

26

26

Pharmaceutical Technology

DECEMBER 26, 2023

AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Sarcomas.

52

52